Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Aytu Biopharma (AYTU) over the last 11 years, with Q4 2025 value amounting to $205418.0.

  • Aytu Biopharma's Gains from Investment Securities fell 721.53% to $205418.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $205418.0, marking a year-over-year decrease of 721.53%. This contributed to the annual value of $211618.0 for FY2025, which is 4441.07% up from last year.
  • According to the latest figures from Q4 2025, Aytu Biopharma's Gains from Investment Securities is $205418.0, which was down 721.53% from $140000.0 recorded in Q3 2025.
  • In the past 5 years, Aytu Biopharma's Gains from Investment Securities ranged from a high of $1.0 million in Q2 2024 and a low of -$2.7 million during Q2 2021
  • Its 5-year average for Gains from Investment Securities is -$110389.5, with a median of $136254.0 in 2021.
  • Over the last 5 years, Aytu Biopharma's Gains from Investment Securities had its largest YoY gain of 48734.05% in 2023, and its largest YoY loss of 9630000.0% in 2023.
  • Aytu Biopharma's Gains from Investment Securities (Quarter) stood at $90731.0 in 2021, then dropped by 17.34% to $75000.0 in 2022, then surged by 98.78% to $149087.0 in 2023, then skyrocketed by 48.5% to $221392.0 in 2024, then decreased by 7.22% to $205418.0 in 2025.
  • Its Gains from Investment Securities was $205418.0 in Q4 2025, compared to $140000.0 in Q3 2025 and $219244.0 in Q1 2025.